Early treatment effect of ruxolitinib in BOS after HCT. Change in FEV1 in liters from baseline after 3 months of ruxolitinib therapy is shown in 41 evaluable participants with BOS. Dotted lines mark absolute improvement by 10%. Treatment cohorts are indicated by color. Each bar represents an individual participant.